t
| Date | 19 May 2022 |
| Time | 07:00:13 |
| Category | Miscellaneous |
| ID | 0253M |
Belluscura PLC
("Belluscura" or the "Company")
Belluscura Expands its Oxygen Enrichment Patent Portfolio
Three New Patents Issue related to Extracorporeal membrane oxygenation (ECMO), Continuous Positive Airway Pressure (CPAP) and Replaceable Molecular Sieve Technology
LONDON, U.K. AND PLANO, TX, U.S. (19 May 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that three additional US patents have recently issued, increasing the number of issued and pending patent applications the Company owns or exclusively licenses to thirty.
The technology covered by the patents, includes:
· Extracorporeal membrane oxygenation (ECMO) innovations for when people who are very ill with conditions of the heart and lungs, or who are waiting for or recovering from a heart transplant, require a portable artificial lung;
· Continuous Positive Airway Pressure (CPAP) innovations, a type of non-invasive ventilation (NIV) or breathing support, and;
· Consumer replaceable molecular sieve technology, used to remove Nitrogen from ordinary air to produce medical grade supplemental oxygen.
Robert Rauker, CEO of Belluscura plc, said: "Our pioneering engineering team continues to develop next generation oxygen enrichment technology along with our research partner, Separation Design Group. We see significant expanding future opportunities in the supplemental oxygen field."
For further information please contact:
|
Belluscura plc |
|
|
Robert Rauker, Chief Executive Officer |
via Walbrook PR |
|
Anthony Dyer, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin |
|
|
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
James Serjeant / Nicholas Chambers |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
Paul McManus / Sam Allen |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.